Epigenetic regulation of Fatty acid amide Hydrolase in Alzheimer disease

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  D'Addario, Claudio ^a   Di Francesco, Andrea ^a   Arosio, Beatrice ^b   Gussago, Cristina ^b   Dell'Osso, Bernardo ^b   Bari, Monica ^c,d   Galimberti, Daniela ^b   Scarpini, Elio ^b   Altamura, A Carlo ^b   Mari, Daniela ^b   Maccarrone, Mauro ^a,d  

^a UNIVERSITY OF TERAMO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOCANNABINOID; FATTY ACID AMIDASE; MESSENGER RNA;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DNA METHYLATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME REGULATION; EPIGENETICS; FAAH GENE; FEMALE; GENE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROMOTER REGION;

AGED; ALZHEIMER DISEASE; AMIDOHYDROLASES; BASE SEQUENCE; DNA PRIMERS; EPIGENESIS, GENETIC; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84862196266     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039186     Document Type: Article

References (56)

1. Lleó A, Greenberg SM, Growdon JH, (2006) Current pharmacotherapy for Alzheimer's disease. Annu Rev Med 57: 513-533.
2. Centonze D, Battistini L, Maccarrone M, (2008) The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases. Curr Pharm Des 14: 2342-2370.
3. Jung KM, Astarita G, Yasar S, Vasilevko V, Cribbs DH, et al. (2011) An amyloid β(42)-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease. Neurobiol Aging doi:10.1016/j.neurobiolaging.2011.03.012.
4. Mechoulam R, Hanus L, (2000) A historical overview of chemical research on cannabinoids. Chem Phys Lipids 108: 1-13.
5. Piomelli D, (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4: 873-884.
6. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, et al. (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2 Pharmacol Rev 62: 588-5631.
7. Di Marzo V, (2008) Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol 160: 1-24.
8. Pisani A, Fezza F, Galati S, Battista N, Napolitano S, et al. (2005) High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann Neurol 57: 777-779.
9. Solinas M, Goldberg SR, Piomelli D, (2008) The endocannabinoid system in brain reward processes. Br J Pharmacol 154: 369-383.
10. Maccarrone M, Dainese E, Oddi S, (2010) Intracellular trafficking of AEA: new concepts for signaling. Trends Biochem Sci 35: 601-608.
11. Benito C, Núñez E, Pazos MR, Tolón RM, Romero J, (2007) The endocannabinoid system and Alzheimer's disease. Mol Neurobiol 36: 75-81.
12. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, et al. (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302: 84-88.
13. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, et al. (2004) Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem 89: 134-141.
14. Paradisi A, Oddi S, Maccarrone M, (2006) The endocannabinoid system in ageing: a new target for drug development. Curr Drug Targets 7: 1539-1552.
15. Mailleux P, Vanderhaeghen JJ, (1992) Age-related loss of cannabinoid receptor binding sites and mRNA in the rat striatum. Neurosci Lett 147: 179-181.
16. Romero J, Berrendero F, Manzanares J, Pérez A, Corchero J, et al. (1998) Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol. Synapse 30: 298-308.
17. Richfield EK, Herkenham M, (1994) Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann Neurol 36: 577-584.
18. Benito C, Núñez E, Tolón RM, Carrier EJ, Rábano A, et al. (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 23: 11136-11141.
19. Lee JH, Agacinski G, Williams JH, Wilcock GK, Esiri MM, et al. (2010) Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex. Neurochem Int 57: 985-989.
20. Mulder J, Zilberter M, Pasquaré SJ, Alpár A, Schulte G, et al. (2011) Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain 134: 1041-1060.
21. Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M, (1994) Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 63: 637-652.
22. Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML, (2005) Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 25: 1904-1913.
23. Núñez E, Benito C, Tolón RM, Hillard CJ, Griffin WS, et al. (2008) Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome. Neuroscience 151: 104-110.
24. Wisniewski KE, Wisniewski HM, Wen GY, (1985) Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 17: 278-282.
25. Grünblatt E, Bartl J, Zehetmayer S, Ringel TM, Bauer P, et al. (2009) Gene expression as peripheral biomarkers for sporadic Alzheimer's disease. J Alzheimers Dis 16: 627-634.
26. Koppel J, Bradshaw H, Goldberg TE, Khalili H, Marambaud P, et al. (2009) Endocannabinoids in Alzheimer's disease and their impact on normative cognitive performance: a case-control and cohort study. Lipids Health Dis 14: 8.
27. Bisogno T, Di Marzo V, (2008) The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses. Curr Pharm Des 14: 2299-3305.
28. Pidsley R, Mill J, (2001) Epigenetic studies of psychosis: current findings, methodological approaches, and implications for postmortem research. Biol Psychiatry 69: 146-156.
29. Tsankova N, Renthal W, Kumar A, Nestler EJ, (2007) Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 8: 355-367.
30. Feng J, Fouse S, Fan G, (2007) Epigenetic regulation of neural gene expression and neuronal function. Pediatr Res 61: 58-63.
31. Gavin DP, Sharma RP, (2010) Histone modifications, DNA methylation, and schizophrenia. Neurosci Biobehav Rev 34: 882-888.
32. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB, (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370: 737-749.
33. Dangond F, Gullans SR, (1998) Differential expression of human histone deacetylase mRNAs in response to immune cell apoptosis induction by trichostatin A and butyrate. Biochem Biophys Res Commun 247: 833-837.
34. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, et al. (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6: 734-746.
35. Arosio B, Trabattoni D, Galimberti L, Bucciarelli P, Fasano F, et al. (2004) Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease. Neurobiol Aging 25: 1009-1015.
36. Folstein M, Folstein S, McHugh P, (1975) "Mini-mental state" J Psychiatr Res 12: 189-198 A practical method for grading the cognitive state of patients for the clinician.
37. Chomczynski P, Sacchi N, (2006) The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nat Protoc 1: 581-585.
38. Miller SA, Dykes DD, Polesky HF, (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215.
39. Brenet F, Moh M, Funk P, Feierstein E, Viale AJ, et al. (2011) DNA methylation of the first exon is tightly linked to transcriptional silencing. PLoS One 6: e14524.
40. Wan Y, Wang Y, Luo J, Lu Z, (2007) Bisulfite modification of immobilized DNAs for methylation detection. Biosens Bioelectron 22: 2415-2421.
41. D'Addario C, Dell'Osso B, Palazzo MC, Benatti B, Lietti L, et al. (2012) Selective DNA methylation of BDNF promoter in bipolar disorder: Differences among patients with BDI and BDII. Neuropsychopharmacology 37: 1647-1655.
42. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, et al. (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 98: 9371-9376.
43. Day TA, Rakhshan F, Deutsch DG, Barker EL, (2001) Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Mol Pharmacol 59: 1369-1375.
44. Campbell VA and Gowran A (2007) Alzheimer's disease; taking the edge off with cannabinoids? British Journal of Pharmacology 152: 655-662.
45. Maccarrone M, Bari M, Battista N, Finazzi-Agrò A, (2002) Estrogen stimulates arachidonoylethanolamide release from human endothelial cells and platelet activation. Blood 100: 4040-4048.
46. Campbell VA, Gowran A, (2007) Alzheimer's disease; taking the edge off with cannabinoids? British Journal of Pharmacology 152: 655-662.
47. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, et al. (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421.
48. Marchalant Y, Cerbai F, Brothers HM, Wenk GL, (2008) Cannabinoid receptor stimulation is anti inflammatory and improves memory in old rats. Neurobiol Aging 29: 1894-1901.
49. Tsou K, Nogueron MI, Muthian S, Sañudo-Pena MC, Hillard CJ, et al. (1998) Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. Neurosci Lett 254: 137-140.
50. Romero J, Hillard CJ, Calero M, Rábano A, (2002) Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study. Brain Res Mol Brain Res 100: 85-93.
51. Catani MV, Gasperi V, Evangelista D, Finazzi Agrò A, Avigliano L, et al. (2010) Anandamide extends platelets survival through CB1-dependent Akt signalling. Cell Mol Life Sci 67: 601-610.
52. Arosio B, Bulbarelli A, Bastias Candia S, Lonati E, Matronardi L, et al. (2011) Pin1 contribution to Alzheimer's disease: Transcriptional and epigenetic mechanisms in patients with late-onset Alzheimer's disease. Neurodegenerative Dis 10: 207-211.
53. Scarpa S, Cavallaro RA, D'Anselmi F, Fuso A, (2006) Gene silencing through methylation: an epigenetic intervention on Alzheimer disease. J Alzheimers Dis 9: 407-414.
54. Wang SC, Oelze B, Schumacher A, (2008) Age-specific epigenetic drift in late-onset Alzheimer's disease. PLoS One 3: e2698.
55. Szekely CA, Town T, Zandi PP, (2007) NSAIDs for the chemoprevention of Alzheimer's disease. Subcell Biochem 42: 229-248.
56. Rouzer CA, Marnett LJ, (2011) Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem Rev 111: 5899-5921.